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Abstract
Background: Lentiviral gene therapy vectors are now finding clinical application. In order to fully
exploit their potential it is important that vectors are made as efficient and as safe as possible.
Accordingly, we have modified a previously reported vector to improve RNA processing, minimise
Human Immunodeficiency Virus Type-1 (HIV-1) sequence content and reduce repair of the self
inactivating (SIN) deletion.
Results: HIV-1 sequence in the vector was reduced by substituting the polyadenylation signal with
a heterologous signal. Mutation of splice donor sites was undertaken to prevent the majority of
splicing within the vector genomic RNA. In addition, a number of other sequences within the vector
were deleted. The combination of these modifications was able to significantly reduce the rates of
both vector mobilisation and repair of the self inactivating deletion after two rounds of marker
rescue.
Conclusion: RNA processing can be improved by mutation of the major and minor HIV-1 splice
donor sites in the vector. In addition the rate of vector mobilisation and repair of SIN vectors can
be successfully reduced by careful vector design that reduces homology between the 5' and 3' long
terminal repeats (LTRs) to a minimum.
Background
Human immunodeficiency Virus Type 1 (HIV-1) derived
gene therapy vectors are being used in the development of
gene therapy treatments of many disorders [1-5], princi-
pally due to their ability to transduce dividing and non-
dividing cells, resulting in long term stable expression of
the desired transgene [6]. Also, compared to their oncoret-
roviral counterparts, once pseudotyped they are relatively
easy to concentrate to high titres [7]. However, fears
regarding the safety of HIV-1 derived vectors have per-
sisted, especially due to the demonstrated oncogenic
potential of other retroviral vectors.
Self Inactivating (SIN) vectors are designed to prevent the
transfer of enhancer and promoter elements in the 5' long
terminal repeat (LTR) of the vector to transduced cells [8].
These vectors contain a deletion in the 3' U3 sequence
which is transferred to the 5' U3 sequence during reverse
transcription, resulting in a provirus that contains no LTR
derived enhancer or promoter elements [8], reducing the
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probability of proviral mediated gene activation. In SIN
vectors, an internal heterologous promoter is used to
express the transgene. As no full length RNA is produced
by the integrated vector, the chances of inducing aberrant
expression of nearby genes via 3' LTR read-through, and
vector mobilisation by other viruses infecting the cell
[8,9], is decreased. SIN vectors also exhibit improved
transgene expression [9], particle production and trans-
duction efficiency [10] compared to their non-SIN coun-
terparts. However, repair of the SIN deletion has been
shown to occur at a measurable frequency [8], meaning
these vectors do not entirely eliminate the possibility of
Replication Competent Retrovirus production, vector
mobilization or gene activation.
These issues are more than hypothetical. The treatment of
X-linked severe combined immunodeficiency (X-SCID)
with an oncoretroviral vector has demonstrated that the
deregulation of gene(s), resulting from the integration of
a viral genome near the gene(s) in question, can have seri-
ous consequences [11-13]. In approximately one quarter
of the patients treated, the virus integrated near to an
oncogene, most commonly LMO2, leading to deregula-
tion of the oncogenic locus and a T cell Acute Lymphob-
lastic Leukaemia. Similarly, in the treatment of X-linked
chronic granulomatous disease using an oncoretroviral
vector, clonal populations have emerged in both patients
treated thus far [14]. Whilst there is a difference in the
integration site preference between oncoretroviral and
lentiviral vectors [15-17], this does not exclude the possi-
bility of a similar result occurring when HIV-1 derived
gene therapy vectors are utilised, especially since repair of
the SIN deletion can occur. This suggests that further
development of lentiviral vectors are required to reduce
safety concerns associated with the use of these vectors.
In this study, in order to improve the safety of the transfer
vector, homology between the transfer vector and HIV-1,
and between the vector LTRs, was reduced, resulting in
decreased rates of SIN repair. In addition, a systematic
analysis of the transfer vector sequence was undertaken to
minimise the amount of HIV-1 sequence within the vector
and to remove signals that adversely impact on the
processing of the viral genomic RNA (gRNA). This analy-
sis was able to prevent splicing of the gRNA, replace the 3'
polyadenylation signal and reduce the size of the transfer
vector.
Results
Splice site modifications
Splicing is used by HIV-1 to produce multiple mRNA tran-
scripts encoding various proteins [18]. However, in the
context of a HIV-1 derived gene transfer vector, splicing is
unnecessary and can lead to a reduction in the amount of
genomic RNA (gRNA) available for packaging. Therefore,
we chose to mutate the HIV-1 splice donor site such that
splicing no longer occurs.
We have previously shown that in our vector pHIV-1SE,
that splicing occurs between the HIV-1 major splice donor
and cryptic splice acceptor sites in the SV40 promoter
sequence [19]. Mutation of the major splice donor site
from GT to CG (pHIV-1SDmSE) reduced but did not
abrogate splicing (Figure 1a, lanes 1 and 2). DNA
sequencing indicated that the residual splicing originated
at the minor splice donor site 2 bases 3' of the major splice
donor site. Therefore, vectors which contained mutations
to both the major and minor splice donor sites were con-
structed. Five different mutations were evaluated, in these
both splice donor sites were mutated from GT to (i) CT
(pHIV-1SDm2SE); (ii) GA (pHIV-1SDm2.1SE); (iii) GG
(pHIV-1SDm2.2SE); (iv) AT (pHIV-1SDm2.3SE) or (v)
GC (pHIV-1SDm2.4SE).
Qualitative RT-PCR showed that all vectors except pHIV-
1SDm2.4SE produce less spliced RNA compared to pHIV-
1SDmSE (Figure 1a). The titres of the vectors pHIV-
1SDm2SE, pHIV-1SDm2.2SE and pHIV-1SDm2.3SE were
equal and approximately 2-fold higher than pHIV-
1SDmSE (p < 0.01, ANOVA/Holm-Sidak) whilst pHIV-
1SDm2.1SE gave a titre equal to pHIV-1SDmSE (Figure
1b). pHIV-1SDm2SE was chosen for further studies as it
offered high titres in combination with very low levels of
residual RNA splicing.
3'U3 modifications
In order to reduce homology between the 5 and 3' LTRs
the effect of replacing the HIV-1 polyadenylation signal
with either the SV40 (Genbank accession number
NC001669, bp 2606 to 2700) or bGH (Genbank acces-
sion number M57764, bp 2413 to 2465) polyadenylation
signals was investigated. For the bGH vector the polyade-
nylation signal was inserted after the AflII site in the R
sequence so that it replaced the last 25 bp of R and all of
U5. For the SV40 vector the polyadenylation signal was
inserted 8 bp after the SacI site in the R sequence so that it
replaced the last 51 bp of R and all of U5. In both con-
structs all of U3, with the exception of the 19 bp att
sequence was deleted, as was all extraneous sequence
between the end of the EYFP coding sequence and the
start of the PPT (we have previously shown that deletion
of the latter sequence has no effect on vector performance
[20]). The resulting constructs were designated
pHIV1SDm2SESVatt19 and pHIV1SDm2SEbGHatt19.
When tested for virus titre using amounts of vector DNA
for transfection (0.125 μg/well) that were limiting for
virus production, there was no significant difference in
titre between the vectors (data not shown). Reducing the
att sequence to 12 bp in length resulted in significantly
lower titres (Figure 2). From this analysis the bGHatt19BMC Biotechnology 2009, 9:86 http://www.biomedcentral.com/1472-6750/9/86
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and SV40att19 constructs appeared equivalent to the
pHIV-1SDm2SE vector, with the apparent advantage that
they contain less HIV-1 sequence than the latter.
Combination gag and 3'U3 deletion vectors
Deletion mapping demonstrated that bases 325-400 of
the gag gene sequence present in our original vector could
be deleted without significantly affecting virus titre (data
Effect of Splice Site Mutation Figure 1
Effect of Splice Site Mutation. (A) Analysis of splicing in 
splice site mutation vectors. RNA from 293T cells trans-
fected with the relevant vector, pcDNA3.1tat101ml and 
pHCMVrevmlwhv [37] was reverse transcribed and PCR was 
used to amplify spliced transcripts as described in Methods. 
The brackets indicate the mutation of the major and minor 
splice donor sites present in each vector. SDm, pHIV-
1SDmSE; SDm2, pHIV-1SDm2SE; SDm2.1, pHIV-1SDm2.1SE; 
SDm2.2, pHIV-1SDm2.2SE; SDm2.3, pHIV-12.3SE; SDm2.4, 
pHIV-1SDm2.4SE. (B) Vector titres using 0.125 ug vector per 
well (see Materials and methods for details). *All SDm2 vari-
ants, with the exception of SDm2.1, had significantly higher 
titres than the parental vector, SDm (ANOVA/Holm-Sidak, p 
< 0.01). In addition, SDm2, SDm2.2, SDm2.3 and SDm2.4 all 
had significantly higher titres than SDm2.1 (ANOVA/Holm-
Sidak, p < 0.01). All results are presented as Mean ± SD (n = 
6).
Effect of 3'U3 alterations on virus titre Figure 2
Effect of 3'U3 alterations on virus titre. (A) Titres of 
vectors containing either the SV40 or bGH polyadenylation 
sites, and either a 12 or 19 bp att sequence were compared 
using 0.125 ug vector per well (n = 3). bGHatt12, pHIV-
1SDm2SEbGHatt12; bGHatt19, pHIV-1SDm2SEbGHatt19; 
SVatt12, pHIV-1SDm2SESVatt12; SVatt19, pHIV-
1SDm2SESVatt19. * = P < 0.05 ANOVA on Ranks. All results 
are presented as Mean ± SD. (B) Schematic of 3' LTR struc-
tures. In both cases R is truncated at the 3' end, att is 12 or 
19 bp in length. SV40, SV40 early polyadenylation signal; 
bGH, bovine growth hormone gene polyadenylation signal 
(see Results for details).
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not shown). This deletion (Δgag) was transferred into
pHIV-1SDm2SEbGHatt19 and pHIV-1SDm2SESVatt19.
In both cases, the addition of this deletion increased the
resulting virus titre compared to the parental vectors (Fig-
ure 3). The vector pHIV-1SDmSE2SV40att19Δgag was
chosen for further analysis as it exhibited the highest titre.
For simplicity, this construct was renamed pRK1.
5'U3 modifications
The HIV-1 5'U3 contains a modulatory region between -
421 and -105, included in which is a negative regulatory
element between -340 and -184 [21,22], as well as core
enhancer and promoter sequences. Deletion mapping
(Figure 4a) was used to determine if the modulatory and
negative regulatory elements are required in the context of
a HIV-1 derived gene transfer vector. In addition, deletion
of the 5'att sequence was assessed as this sequence would
appear to be redundant given that the att  sequence is
duplicated from the 3' LTR upon reverse transcription.
The titres of pRK1Δatt, pRK1Δatt340/184 and pRK1340/
184 were not significantly different to that of pRK1 (Fig-
ure 4b) while all the other deletions lead to a significant
decrease in virus titre (p < 0.05, ANOVA on ranks with
Dunns Multiple Comparisons).
5' polyadenylation signal
Retroviral polyadenylation signals are thought to be
inherently leaky as they must allow read-through of the 5'
LTR so that the genome can be efficiently transcribed [21].
While substitution of the HIV-1 polyadenylation signal
with the SV40 polyadenylation signal in the 3' LTR of the
vector results in the SV40 polyadenylation signal being
utilised during virus production, during reverse transcrip-
tion it is 5'R/U5 which acts as a template for the cDNA,
resulting in the HIV-1 polyadenylation signal being used
in the resulting provirus. Therefore, to change the polya-
denylation signal used in transduced cells, the sequence of
the polyadenylation signal in the 5' LTR must be replaced.
To this end the bGH polyadenylation signal was inserted
into the 5'LTR of pRK1Δatt340/184. As the bGH polyade-
nylation signal contains a downstream sequence element
(DSE) that increases the accuracy, but not efficiency of
polyadenylation, two variants were created, one without
(pRK1Δatt340/184bGH, renamed pRK2), and one with
(pRK1Δatt340/184bGHDSE renamed pRK2DSE) the
bGH polyadenylation signal DSE (Genbank M57764
bases 2422-2440 and 2422-2465 respectively) inserted
after the AATAAA motif in R, so as to replace the last 19 bp
of R (Figure 5a). In both these constructs a small decrease
in virus titre was seen (Figure 5b) compared with the
parental vector (P < 0.05 ANOVA on Ranks with Dunns
Multiple Comparison).
We then assessed whether the use of the bGH polyade-
nylation signal in the provirus resulted in reduced tran-
Effect of combination gag and 3'U3 modifications on virus  titre Figure 3
Effect of combination gag and 3'U3 modifications on 
virus titre. (A) Vectors containing both the Δgag and 3'U3 
deletions were compared for virus titre using 0.125 ug vec-
tor per well. bGHatt19, pHIV1SDm2SEbGHatt19; 
bGHatt19Δgag, pHIV1SDm2SEbGHatt19Δgag; SVatt19, 
pHIV1SDm2SESVatt19; SVatt19Δgag, 
pHIV1SDm2SESVatt19Δgag (pRK1). * = P < 0.001, ANOVA 
with Holm-Sidak multiple comparison. All results are pre-
sented as Mean ± SD (n = 6). (B) Schematic of 5' LTR and gag 
gene sequence and 3' LTR variants present in the constructs 
tested. The region of the gag gene deleted in the "Δgag" con-
structs is indicated by cross hatching. All constructs contain a 
19 bp att sequence in the 3' LTR and the R sequence is trun-
cated at the 3' end.
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Effect of 5'U3 deletions on virus titre Figure 4
Effect of 5'U3 deletions on virus titre. (A) Schematic showing the deletions to the modulatory region of 5'U3 that were 
analysed. att, integration signal; Sp1, Sp1 binding site; CE, core enhancer. (B) Vector titres using 1 ug vector per well. * = P < 
0.05 vs. pRK1, ANOVA on Ranks with Dunns multiple comparison. All results are presented as Mean ± SD (n = 6).
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scriptional read-through compared with the HIV-1 signal.
To allow this, vectors which had the structure of the 3' LTR
post reverse transcription were created for pRK2 and
pRK2DSE giving the vectors pRK2prt and pRK2DSEprt.
The vector pHIV-1SDmSE was also analysed for read-
through. However, as the structure of the 3' LTR pre and
post reverse transcription in pHIV-1SDmSE is unchanged,
this vector could be tested without modification. Each
vector construct was transfected into 293T cells along with
constructs expressing Tat and Rev and the resulting mRNA
isolated and reverse transcribed. The total amount of vec-
tor transcripts, and the amount that is contiguous with
sequences 3' of the polyadenylation signal, were then
determined to allow the frequency of polyadenylation sig-
nal read-through to be measured. This was done using two
real time PCR assays; one that detects the eyfp sequence
present in the vector, and one that detects sequence span-
ning from eyfp into the pBCKS cloning vector (i.e. read-
through transcript) (Figure 6).
The results of this assay (Table 1) indicated that the post
reverse transcription 3' LTRs from both pRK2 and
pRK2DSE actually exhibit increased levels of polyadenyla-
tion signal read-through compared to pHIV-1SDmSE.
Therefore, these vectors were not considered further and
the vector pRK1Δatt340/184 was chosen for further
assessment.
Detailed Comparison of pRK1 and pRK1Δatt340/184 with 
pHIV-1SDmSE
The pRK1 and pRK1Δatt340/184 vectors were directly
compared with the parental plasmid pHIV-1SDmSE in a
number of assays to see if the changes incorporated into
pRK1 and pRK1Δatt340/184 resulted in an improved vec-
tor. Assessment of titre showed that both the modified
vectors had a small (approximately 1/4) but significant (p
< 0.01, ANOVA) reduction in titre compared with pHIV-
1SDmSE (Figure 7). We note that the titres reported in Fig-
ure 7 are significantly higher than those reported in Figure
4. Our best explanation for this is that the experiments
were done over 1 year apart, and used different batches of
transfection reagents and cells cultured from different
stocks.
The effect of insertion of the bGH polyadenylation signal into  the 5' LTR Figure 5
The effect of insertion of the bGH polyadenylation 
signal into the 5' LTR. The bGH polyadenylation signal 
was inserted into the 5' LTR with (pRK2DSE), or without 
(pRK2), the downstream regulatory element and vector 
titres assessed. (A) Sequence of insertions made. The 
AATAAA motif is shown bold and the bGH sequence is 
underlined. (B) Vector titres using 1 ug vector per well. * = P 
< 0.05 vs pRK1Δatt340/184 ANOVA on Ranks with Dunns 
Multiple Comparison All results are presented as Mean ± SD 
(n = 6).
pRK2
U5
TCAATAAAATGAGGAAATTGCATCGCAAGTAGTG
pRK2DSE
U5
TCAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTAGTAGTG
A
B
pRK1ǻatt340/184 pRK2 pRK2DSE
T
i
t
r
e
 
(
x
1
0
6
N
I
H
3
T
3
 
I
U
/
m
L
)
0
1
2
3
4
5
* *
Assay for transcriptional read-through of the 3' LTR Figure 6
Assay for transcriptional read-through of the 3' LTR. 
Arrows indicate the real time PCR product and the solid tri-
angle the position of the TaqMan probe. EYFP, enhanced yel-
low fluorescent protein; LTR, 3' long terminal repeat 
sequence.
EYFP LTR
pBCKS
EYFP
EYFP-pBCKS
Table 1: Rate of polyadenylation read-through (n = 3)
Vector Frequency of Read-througha
pHIV-1SDmSE 9.05 ± 0.93 × 10-3
pRK2 8.70 ± 2.41 × 10-3
pRK2prt 8.57 ± 3.50 × 10-2
pRK2DSE 1.35 ± 0.41 × 10-2
pRK2DSEprt 8.72 ± 1.42 × 10-2b
aReal time PCR was used to determine the frequency of 
polyadenylation signal read-through in 293T cells transduced with the 
vector, pcDNA3.1Tat101ml and pHCMVrevnlwhvpre. Results are 
Mean ± SD.
bP < 0.05 vs pHIV-1SDmSE, pRK2 and pRK2DSE, t-testBMC Biotechnology 2009, 9:86 http://www.biomedcentral.com/1472-6750/9/86
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The propensity for pRK1neo and pRK1Δatt340/184neo to
repair the SIN deletion in the 3'LTR was then assessed
using a marker rescue assay. For this analysis vectors car-
rying the neomycin resistance gene were used in order to
be able to detect unitary events. In this assay, cells which
have been transduced by each virus are transfected with
plasmids encoding proteins necessary for virus produc-
tion (i.e. Tat, Rev, GagPol and VSV-G). If the deletion is
repaired, the cell will contain full length genomic tran-
scripts which can be packaged, resulting in virus produc-
tion. However, it is also possible that transcription from a
nearby upstream active promoter will result in a packaga-
ble message. Therefore, to selectively amplify the events
where the LTR has been repaired, the virus rescued in the
first instance was used to transduce cells and a second
round of rescue performed. The vectors pHIV-
1SDmSneoLTR (a vector containing unmodified and
intact 5' and 3' LTRs), and pHIV-1SDmSneo were utilised
as assay controls.
After 2 rounds of rescue, pHIV-1SDmSneo was rescued 2-
fold more efficiently than pRK1neo (P = 0.129, t-test) and
8.5-fold more efficiently than pRK1Δatt340/184neo (P <
0.03, t-test) (Table 2), meaning pRK1Δatt340/184neo was
rescued 4.4-fold less efficiently than pRK1neo (P < 0.005,
t-test). To further examine the differences between these
vectors, individual neomycin resistant colonies from the
virus assay of the round 2 rescued virus were isolated
using cloning rings and the genomic DNA analysed for the
structure of the 5' LTR using PCR. The 5' primer for this
PCR was designed to bind to the att sequence in the 5' LTR
and the 3' primer to the primer binding site. A fully
repaired 5' LTR will give a PCR product of 649 (pHIV-
1SDmSneo and pRK1neo) or 539 (pRK1Δatt340/184neo)
bases, whilst a non-repaired SIN 5' LTR will result in a PCR
product of 244 (pHIV-1SDmSneo), or 200 (pRK1neo and
pRK1Δatt340/184neo) bases (Figure 8). All colonies
examined from pHIV-1SDmSneo and pHIV-
1SDmSneoLTR exhibited fully repaired LTRs. In contrast
18% (4/22) of the colonies from pRK1neo that yielded
Titre comparison of pHIV-1SDmSE, pRK1 and pRK1Δatt340/ 184 Figure 7
Titre comparison of pHIV-1SDmSE, pRK1 and 
pRK1Δatt340/184. (A) The titre of pHIV-1SDmSE, pRK1 
and pRK1Δatt340/184 using 1 ug vector per well. *P < 0.01 
versus pHIV-1SDmSE ANOVA All results are presented as 
Mean ± SD (n = 18). (B) Schematic diagrams of the vectors 
assessed. Grey vertical bar represent the att sequence; LTR, 
long terminal repeat; diagonal cross hatching, R sequence; 
horizontal hatching, U5 sequence; SDm(2), mutagenised 
splice donor site(s); gag, gag gene sequence; rre, Rev 
response element; c, central polypurine tract; SV, SV40 early 
promoter; eYFP, enhanced yellow fluorescent protein coding 
sequence, Δ, SIN LTR; vertical hatching, SV40 polyadenyla-
tion signal.
pHIV-1SDmSE pRK1 pRK1ǻatt340/184
T
i
t
r
e
 
x
 
1
0
6
N
I
H
3
T
3
 
I
U
/
m
L
0
5
10
15
20
25
* *
pHIV-1SDmSE
gag rre SV eYFP c LTR
S
D
m
'
'gag rre SV eYFP c LTR
S
D
m
2 pRK1
'gag rre SV eYFP c LTR
S
D
m
2 pRK1 att340/184
A
B
Structure of proviral 5' LTRs after reverse transcription and  integration Figure 8
Structure of proviral 5' LTRs after reverse transcrip-
tion and integration. The predicted structures of the 5' 
LTRs, both SIN and repaired, for the pHIV-1SDmSneo, 
pRK1neo and pRK1Δatt340/184neo vectors, and the corre-
sponding size of the expected PCR product from analysis of 
genomic DNA with the primers int19 and Nar1R are shown. 
(A) pHIV-1SDmSneo SIN LTR; (B) pRK1neo/pRK1Δatt340/
184neo SIN LTR; (C) pRK1Δatt340/184neo repaired LTR; 
(D) pHIV-1SDmSneo/pRK1neo repaired LTR. See Methods 
for details and Table 2 for results.
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PCR products, and 32% (4/11) of the colonies from
pRK1Δatt340/184neo that yielded PCR products, were
indicative of non-repaired SIN LTRs, demonstrating a sig-
nificant improvement in the maintenance of the SIN phe-
notype in pRK1Δatt340/184neo (Table 2)
(pHIV1SDmSneo v pRK1Δatt340/184neo P < 0.002,
Fisher's exact Chi squared) but not in pRK1neo. The cor-
responding numbers for fully repaired LTRs were 59%
(13/22) and 17% (2/11), respectively, meaning the rate of
fully repaired LTRs was significantly reduced in
pRK1Δatt340/184neo compared to both pRK1neo and
pHIV-1SDmSneo (Fisher's exact Chi squared, p < 0.05 and
p < 0.0001, respectively). Both pRK1neo (22% of colonies
yielding PCR products) and pRK1Δatt340/184neo (42%
of colonies yielding PCR products) also gave some PCR
products of a size intermediate between the SIN LTR and
the fully repaired LTR. Sequence analysis of intermediate
size PCR products from pRK1Δatt340/184neo showed
partial repair of the U3 sequence, with the sequence trun-
cated at the 5' end. Of the 5 clones of this type that were
successfully analysed, 4 also contained partial duplica-
tions of the R/SV40 polyadenylation sequence from the 3'
LTR (Figure 9). In addition, while all colonies derived
from pHIV-1SDmSneo and pHIV-1SDmSneoLTR yielded
PCR products, 1 out of 23 colonies from pRK1neo, and 8
of 20 colonies from pRK1Δatt340/184neo, did not yield a
PCR product, suggesting that at least one of the PCR
primer sequences was missing.
Discussion
While the broad design features for a successful lentiviral
vector have been apparent for some time, we believe that
refinement of vector design can lead to significant
improvements in vector performance. As the issue of the
production of replication competent virus appears to have
already been solved in third generation lentiviral vector
systems, in this study we have focussed on improving our
vector in two ways (i) by improving RNA processing by
minimising splicing and (ii) reducing the propensity for
SIN repair and vector mobilisation, while maintaining
vector titre, a principle determinate of vector utility.
In our analyses we generally found that intra-experiment
variation was much less than the variation between exper-
iments, and that the latter was greatly reduced if the exper-
iment was repeated relatively contemporarily. In all cases,
the observed relative differences between vectors were
highly reproducible, even if the absolute titres were less
so.
Splicing has an important role to play in the HIV-1 lifecy-
cle. By alternately splicing the 9 kb genome, mRNA encod-
ing multiple proteins can be produced [10]. However, this
process is irrelevant in the context of a HIV-1 gene transfer
vector, and can result in a decrease in the amount of full
length gRNA available for packaging. Mutation of the
cryptic splice acceptor sites in our vector had previously
been attempted but was unable to reduce the amount of
splicing as it resulted in other cryptic splice acceptor sites
being used (D. Anson, unpublished). Therefore, we chose
to mutate both the major and minor HIV-1 splice donor
sites as cryptic splice donor sites appear to be less com-
mon. This is presumably due to the more rigid consensus
sequence for splice donor sites (AGGURUAGU) than
splice acceptor sites (NAGG) [23].
Mutation of the HIV-1 major splice donor site has been
previously attempted [24]. The site was mutated from GT
to CA or GG. These modifications were only able to pre-
vent splicing to a limited extent due to the activity of the
HIV-1 minor splice donor site. In the present study splic-
ing could only be reduced by simultaneously mutating
both the major and minor splice sites. However, not all
mutations were equally effective. Closer examination
revealed the mutations which contained a purine as the
second base of the mutation lead to a significant increase
in virus titre and a reduced amount of splicing. As the
splice donor sites are very close to the highly structured
Sequence analysis of intermediate size PCR products from  the pRK1Δatt340/184neo rescue assay Figure 9
Sequence analysis of intermediate size PCR products 
from the pRK1Δatt340/184neo rescue assay. DNA was 
prepared from colonies arising from the second round of the 
pRK1Δatt340/184neo provirus rescue assay and analysed by 
PCR as described in Methods. PCR products that were inter-
mediate in size to the SIN LTR and the repaired LTR were 
sequenced and showed partial repair of the U3 sequence, 
with the sequence truncated at the 5' end. Four of these 
clones also contained partial duplications of the R/SV40 poly-
adenylation sequence from the 3' LTR. Δatt 3' LTR, structure 
of the 3' LTR from pRK1Δatt340/184neo; Δatt 5' LTR, struc-
ture of the 5' LTR from pRK1Δatt340/184neo; predicted 
post-RT 5' LTR, structure of the pRK1Δatt340/184neo provi-
ral 5' LTR after reverse transcription and integration; 5' LTR 
variant 1 and 2, structure of sequenced PCR products for 
which the PCR product did not correspond to the size pre-
dicted for the SIN or the repaired LTR. Of the 5 PCR prod-
ucts sequenced, 4 corresponded to variant 2.
att 3' LTR
att 5' LTR
Predicted post-RT 5’ LTR
5’ LTR Variant 1 (1/5)
5’ LTR Variant 2 (4/5)
R R SV p(A)
R U3 U5
R U5
R U5 U3
R U5 U3 R SVBMC Biotechnology 2009, 9:86 http://www.biomedcentral.com/1472-6750/9/86
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packaging signal [21], this requirement for a purine as the
second base of the splice donor sites may be due to the
effect of the mutation on the secondary structure of the
mRNA. The residual amount of splicing seen is most likely
due to the use of cryptic splice donor sites [25]. Presuma-
bly, the mutation of the major and minor splice donor
sites would be effective in reducing splicing to any splice
acceptor in the vector, and therefore provides a general
method for reducing unwanted vector splicing.
Modifications to the 3' LTR were able to reduce the
amount of HIV-1 sequence within the vector. The HIV-1
polyadenylation signal was successfully substituted with
the bGH or SV40 polyadenylation signal. In addition all
of U3, except the att sequence, was successfully deleted.
Due to conflicting reports regarding the exact size of att
[26,27], both 12 and 19 bp sequences were assessed. In
both vectors, the use of the 19 bp att sequence resulted in
higher virus titres.
Deletion mapping was used to identify a 75 bp sequence
in gag which was able to be removed from the transfer vec-
tor without significantly affecting virus titre. This region
can be mapped to a Cis Repressive Sequence (CRS) within
gag. These CRS are responsible for the retention of the
unspliced HIV-1 mRNA in the nucleus prior to production
of Rev [28,29]. There are many CRS sequences within gag,
4 of which are within the gag coding sequence in the trans-
fer vector. The deletion described here was able to remove
one of these regions. The removal of the others was not
possible as their sequences are necessary for efficient virus
production. However, mutation of these CRS elements is
possible and has been shown to lead to Rev independent
Gag expression in HIV-1 [29,30]. Therefore, it may be
beneficial to examine these mutations in the context of
the transfer vector to determine their effect on gRNA levels
and virus production. However, whether this would result
in a Rev independent vector is unclear. The CRS elements
direct the mRNA to distinct intranuclear locations [31]
allowing the mRNA to bind to Rev and exit the nucleus
along the correct pathway [32]. By deleting them, the
mRNA may not exit the nucleus along the correct path-
way, which may have repercussions for the viral assembly
process and hence titre.
Within the field of lentiviral gene therapy vectors, most
groups have chosen to replace the 5' LTR with a constitu-
tive promoter (usually CMV) to allow Tat independent
transcription [33,34]. This reduces the number of plas-
mids required for the production of the vector and also
reduces the amount of HIV-1 sequence within the produc-
tion system as a whole, and is assumed to reduce the prob-
ability of RCL being produced and of SIN deletion repair
occurring. However, given that none of the third genera-
tion vector systems generate measurable RCL, and SIN
repair is not usually assessed, the degree to which this
approach to vector design improves safety is hard to
assess. We note that the use of a heterologous promoter to
replace U3 in the 5' LTR also removes a level of regulation
from the vector, and that using the HIV-1 5' LTR requires
that an additional recombination step must occur (i.e. the
Tat coding sequence must be present) for the formation of
a replication competent lentivirus, or for active transcrip-
tion of a provirus via a repaired SIN deletion (see below)
to take place. In our view, this means that the retention of
the HIV-1 5' LTR in the vector may be preferable. Clearly,
these two approaches to vector design need to be directly
compared with respect to (i) the likelihood of generating
RCL, and (ii) the rate of SIN repair, to resolve which is
preferable. Given that measurable RCL is not generated by
advanced lentiviral vector systems, a surrogate assay, such
as quantitative assessment of recombination intermedi-
ate(s) that could lead to the generation of RCL may be a
more appropriate assay to use.
The 5' LTR contains many regulatory elements, most of
which are within U3 [21,22]. Included in this sequence is
the modulatory region which, whilst important for wild
Table 2: Marker rescue assay (n = 3)
Vector IU recovered/IU addeda Frequency of SIN 5' LTRd Frequency of complete 5' LTRe
Round 1b Round 2c
pHIV-1SDmSneo 7.79 ± 0.62 × 10-5 0.21 ± 0.09 0% (0/17) 100% (17/17)
pHIV1SDmSneoLTR 0.71 ± 0.12 0.22 ± 0.40 0% (0/15) 100% (15/15)
pRK1neo 1.14 ± 0.47 × 10-4 0.11 ± 0.02 18% (4/22) 59% (13/22)
pRK1Δatt340/184neo 5.56 ± 1.33 × 10-5 2.52 ± 1.73 × 10-2 32% (4/11) 17% (2/11)
aEach vector was used to transfect 293T cells and subsequently rescued by transfection with pCMVΔRnr and pHCMV-g. The virus rescued in round 
1 was used in a second round of transfection/rescue. Mean ± SD. bThe titre of rescued virus as determined on A549 cells and normalised to the 
amount of virus initially added. cThe titre of the virus rescued in the second transfection and normalised to the amount of virus rescued in round 1. 
dIndividual neomycin resistant colonies from the second round titre assay were analyzed via PCR for the structure of the 5'LTR (see also Figure 8), 
pRK1Δatt340/184neo significantly different to pHIV-1SDmSneo (Fisher's exact Chi squared, p < 0.002). eRepair refers only to LTRs having a 
complete U3 sequence as determined from PCR analysis (pRK1Δatt340/184neo significantly different to pHIV1SDmSneo (p < 0.0001) and pRK1neo 
p < 0.05, Fisher's exact Chi squared). For pRK1neo 5 colonies produced PCR products of intermediate size and one colony out of 23 did not yield 
a PCR product. For pRK1Δatt340/184neo 5 colonies produced PCR products of intermediate size (see also Figure 9) and 8/20 colonies did not yield 
a PCR product. Colonies not producing PCR products were not scored in the results shown above.BMC Biotechnology 2009, 9:86 http://www.biomedcentral.com/1472-6750/9/86
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type HIV-1, may not be required in the context of a HIV-1
derived gene transfer vector. Deletion mapping estab-
lished that the negative regulatory element (from -340 bp
to -184 bp) within the modulatory region was not
required. In addition, the att sequence in the 5' LTR could
also be deleted as this sequence is also not required in the
context of a HIV-1 derived gene transfer vector (the att
sequence in the 3' LTR being copied to the 5' LTR during
reverse transcription).
We also successfully showed that a heterologous polyade-
nylation signal could be incorporated into the 5' LTR, and
hence the provirus. The use of the bGH polyadenylation
signal, either with or without the downstream sequence
element, to replace the HIV-1 polyadenylation signal in
the 5' LTR was successful in vectors containing an SV40
polyadenylation signal in the 3' LTR. However, when
tested, it was shown that insertion of the bGH polyade-
nylation signal resulted in an increase in polyadenylation
signal read-through in the provirus. Therefore, the use of
a heterologous polyadenylation signal in the 5' LTR, while
technically possible, does not appear to offer any advan-
tages in polyadenylation efficiency over the HIV-1 signal,
and so was not used in our final vectors. A similar vector
in which the SV40 polyadenylation signal was incorpo-
rated into the 5' LTR was unsuccessful, with titre being
reduced to very low levels (data not shown). These results
may reflect the inherent conflict between the necessity for
poly(A) read-through in the 5' LTR and the wish for effi-
cient polyadenylation in the 3' LTR.
Detailed comparison of pHIV-1SDmSneo, pRK1neo and
pRK1Δatt340/184neo showed that there was a significant
difference in the ability of the viral genome to be rescued
upon expression of packaging functions. The use of two
rounds of rescue in our assay was vital in showing this dif-
ference. Previous attempts to measure the rate of SIN
repair have analysed repair after a single round of trans-
duction [8,35]. However, this does not distinguish
between repair of the promoter and transcription from
cryptic promoters upstream of the LTR [36]. The tran-
scripts from cryptic promoters do not contain a repaired
LTR, and therefore are unlikely to produce virus capable of
undergoing a further round of replication. The power of
our 2-stage assay is exemplified by the fact that with pHIV-
1SDmSneo, 100% of first round colonies examined for
LTR status were SIN, (data not shown) while 100% of sec-
ond round colonies were repaired, demonstrating
extremely strong selection for LTR repair in the assay.
Interestingly, it was only when homology between the U3
regions had been completely eliminated that the rate of
SIN repair was significantly reduced. Even when homol-
ogy was reduced to just 19 bases in the U3 regions, as in
pRK1neo, the rate of rescue was only reduced two-fold,
which was not significantly different to pHIV-1SDmSneo.
Similarly, while the percentage of complete repair of the
SIN deletion in secondary isolates was reduced, this was
only to 59% of the rate in pHIV-1SDmSneo and again was
not significantly different from pHIV-1SDmSneo. In fact,
repair still occurred in the absence of any homology
between the U3 regions, as in pRK1Δatt340/184neo.
However, in this instance there was a significant reduction
in both the rate of rescue, and the percentage of repaired
LTRs compared to pHIV-1SDmSneo and to pRK1neo, and
a significant increase in the percentage of SIN LTRs com-
pared to pHIV-1SDmSneo. Sequence analysis of colonies
from the pRK1Δatt340/184neo colonies showed that the
PCR products of the size predicted for repaired LTRs with
a complete U3 sequence or retaining the full SIN deletion
(Figure 8) were indeed of the expected structure. In addi-
tion, partially repaired LTR sequences were also seen
which contain a U3 sequence truncated at the 5' end, sev-
eral of these LTRs also contained partial repeats of the R
and SV40 sequences (Figure 9). These characteristics
(reduced rescue and reduced SIN deletion repair) of
pRK1Δatt340/184neo should reduce the probability of
vector mobilisation and of a replication competent virus
being produced. Whilst the mechanism of repair is
unclear, one possibility is that repair may occur during the
reverse transcription process. This in turn would suggest
that the use of stable cell lines to produce HIV-1 derived
vectors may not eliminate the issue of SIN repair.
This finding also has important implications for HIV-1
vector design. A number of groups have chosen to replace
the HIV-1 5'U3 sequence with a CMV promoter [33,34]. If
similar SIN deletion repair (i.e. repair not requiring
sequence homology between the U3 region of the 5' and
3' LTRs) occurred in these vectors, transduced cells would
contain a hybrid LTR with strong CMV derived enhancer
elements, increasing the potential for both virus rescue/
mobilisation and enhancer mediated gene activation [12].
By using the HIV-1 promoter to drive transcription of the
viral genome during production, even if recombination
does occur, the provirus should remain transcriptionally
silent, reducing the probability of vector mobilisation,
although the issue of enhancer mediated gene activation
would remain. In our view further investigation is war-
ranted to determine the mechanisms of SIN deletion
repair in vectors with non-homologous U3 sequences,
and to determine if such repair occurs in vectors with het-
erologous 5' LTR (U3) promoters. If SIN deletion repair
does occur in vectors with heterologous 5' LTR (U3) pro-
moters then the suitability of these vectors for clinical
application may need to be re-evaluated.
Conclusion
Our careful systematic analysis of the vector sequence has
improved RNA processing and more importantly has
allowed a reduction in the amount of HIV-1 sequenceBMC Biotechnology 2009, 9:86 http://www.biomedcentral.com/1472-6750/9/86
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within the vector resulting in significant improvements in
the rate of repair of the SIN deletion.
Methods
Cell Culture
All cell lines were maintained at 37°C/5% CO2 with regu-
lar subculturing using a trypsin/EDTA solution (SAFC Bio-
sciences) as required. 293T (ATCC CRL 11268) and A549
(ATCC CCL 185) cells were maintained in DMEM/5% (v/
v) FCS containing 4.5 g/L glucose and 4 mM glutamine
(SAFC Biosciences). NIH3T3 (ATCC CRL 1658) cells were
maintained in DMEM/10% (v/v) FCS containing 4.5 g/L
glucose and 4 mM glutamine (SAFC Biosciences).
Plasmid Construction
Plasmids were created utilising standard DNA cloning
methods. The parental vector pHIV-1SDmSE has been
previously described [37].
Virus Production
293T cells were plated 24 hours prior to transfection at a
density of 0.9 × 106 cells in 2 mL DMEM/5% (v/v) FCS per
well of a 6 well plate. The cells were then transduced by
calcium phosphate co-precipitation as previously
described [37]. Each well was transfected with 1 or 0.125
μg of the appropriate transfer vector, 1.5 μg pCMVΔRnr
[2] and 0.5 μg of pCMV-g [38]. Eight hours post transfec-
tion the media was exchanged for fresh DMEM/5% (v/v)
FCS and the virus harvested 48 hours post transfection.
Virus Titre Assays
EYFP
Viral titres of EYFP lentiviruses were determined on
NIH3T3 cells using FACScan analysis. NIH3T3 cells were
plated at a density of 0.25 × 106 cells in 0.5 mL medium
per well of a 24 well plate. Three hours later the media was
changed for medium supplemented with 4 μg per mL
polybrene (Sigma) and 50 μg per mL Gentamycin (Sigma)
and an appropriate volume of virus was added such that
5-20% of the cells would be positive for EYFP expression.
The media was exchanged for growth medium after 24
hours and incubation continued for a further 24 hours.
The cells were then split 1:2 and cultured for another 24
hours. The cells were then harvested, the live cell popula-
tion was gated by side and forward scatter and EYFP
expression analysed through the FITC channel on a Bec-
ton Dickinson FACScan Machine. The results were ana-
lysed using Cell-quest software (version 3.0.1f, Becton
Dickinson).
Neomycin Resistance
A549 cells were plated at a density of 0.5 × 106 cells/well
in a 12 well plate (1 mL/well). After 3 hours incubation,
the media was changed for DMEM/5% (v/v) FCS/4 μg per
mL polybrene (Sigma) and an appropriate amount of
virus was added (aiming for between 10 and 100 IU/
well). The assay was incubated at 37°C/5% CO2 for 24
hours before the cells in each well were transferred to a
100 mm dish containing 12 mL DMEM/5% (v/v) FCS and
cultured for a further 24 hours. The media was then
changed for DMEM/5% (v/v) FCS/1 mg per mL active
G418 (Invitrogen) and the plates incubated for a further
10 days, changing the media every 4-5 days or when a lot
of dead cells were present. Once most of the cells were
dead/detached, the G418 content of the media was
reduced to 0.5 mg/mL and the plates incubated until dis-
tinct colonies were present. The colonies were then fixed
in 1:3 Acetic acid: Methanol, stained with 0.1% (w/v)
Trypan Blue (Gibco-BRL) and counted.
Marker Rescue Assay
293T cells were plated at 2 × 106 cells in 4.5 mL in 60 mm
dishes and incubated at 37°C/5% CO2 for 3 hours, after
which the media was replaced with 1 mL of 0.45 μm fil-
tered virus and 4 mL DMEM/5% (v/v) FCS and made 4
μg/mL (final) polybrene (Sigma). The cells were incu-
bated at 37°C/5% CO2 for 24 hours before being split
into 2 × T75 and cultured for 7 days with subculturing per-
formed when required. The media was collected and titred
for residual virus and the transduced 293T cells were
plated in 2 × 150 mm dishes at a density of 1.4 × 107 cells
in 30 mL of medium and incubated at 37°C/5% CO2 for
24 hours, after which 16.2 μg of pCMVΔRnr and 10.8 μg
of pHCMV-g were transfected via calcium phosphate co-
precipitation to one plate, and 27 μg of pBluescript trans-
fected into the second, which served as a control. Eight
hours post transfection, the culture media was changed
for 35 mL DMEM/5% FCS prewarmed to 37°C. The
media was collected 48 hours post transfection, concen-
trated via ultracentrifugation (Beckman Optima L-100K)
in a SW32 rotor at 50,000 g for 90 minutes at 4°C and
assayed for virus titre. The rescued virus was also applied
to fresh 293T cells and the rescue cycle performed once
more. After the second round of rescue, virus was again
titred and 19-23 neomycin resistant colonies from each
group were isolated using cloning rings, expanded and
genomic DNA prepared and assayed to determine the 5'
LTR status of the integrated provirus by PCR.
PCR for 5'LTR status
Genomic DNA was isolated using the Wizard SV genomic
DNA Isolation kit (Promega). Two point five μL of gDNA
was combined with 1 μg of primer INT19 (5' TGGAAG-
GGCTAATTCACTC 3'), 1 μg of primer Nar1R (5' CGG
GCGCCACTGCTAGAGATTTTCC 3'), 100 μM dNTPs, 1 ×
Qiagen PCR buffer and 2.5 Units of Hot Star Taq DNA
polymerase (Qiagen). The reaction was cycled under the
following conditions; 95°C 15 minutes, followed by 35
cycles of 95°C 30 seconds, 60°C 30 seconds, 72°C 30 sec-
onds, followed by 72°C 10 minutes. The PCRs were thenBMC Biotechnology 2009, 9:86 http://www.biomedcentral.com/1472-6750/9/86
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examined on a 3% agarose gel. A repaired/full length LTR
exhibited a size of 649 bp for pHIV-1SDmSneo and
pRK1neo, and 539 bp for pRK1Δatt340/184neo, whereas
a 5' deleted LTR exhibited a size of 200 for pRK1neo and
pRK1Δatt340/184neo and 244 bp for pHIV-1SDmSneo.
RNA analysis
RNA isolation
293T cells were plated at a density of 0.625 × 106 cells in
2 mL per well in a 6 well plate and incubated for 24 hours.
Fugene-6 (Roche) was used to transfect 3.3 μg of the
appropriate vector combined with 100 ng each of
pcDNA3Tat101ml and of pHCMVRevmlwhvpre [37].
Eight hours post transfection, the media was aspirated
and replaced with fresh prewarmed media. The cells were
cultured for a further 40 hours, harvested, washed in PBS
and recovered via centrifugation. RNA was isolated using
TRIZol (Invitrogen) according to the manufacturer's
instructions.
Analysis of Spliced Transcripts
Reverse Transcriptase PCR was performed using Thermo-
script Reverse Transcriptase PCR system (Invitrogen) fol-
lowing the recommended method, and using five
hundred nanograms of RNA and an oligo dT primer. Four
microlitres of cDNA was used in a PCR containing 1 μg of
primers PBSF (5' GGGCCCCGAACAGGGACTTG 3') and
EYR (5' GGGCCCATATGCTTTACTTGTACAGCT 3'), 1 ×
Qiagen PCR buffer and Hot Star Taq DNA polymerase
(Qiagen) under the following conditions; 94°C 45 sec-
onds, 55°C 30 seconds, 72°C 2 minutes for 35 cycles.
PCRs were analysed on a 3% agarose gel to determine
splicing patterns.
Polyadenylation signal readthrough assay
RNA was treated with TURBO DNAse (Ambion) and
reverse transcribed using Thermoscript Reverse Transcrip-
tion Kit (Invitrogen) with random hexamer primers. The
cDNA was then assayed using the eyfp (forward primer 5'
ACGGCCCCGTGCTG 3' probe 5' FAM-CTGCCCGACA
ACCACT-NFQ 3' and reverse primer 5' AGGGCGGACT-
GGTAGCT 3') and eyfp to pBCKS (forward primer 5'
GAGAAGCGCGATCACATGGT 3' probe 5' FAM-CTGCT-
GGAGTTCGTGACCGCCG-NFQ 3' reverse primer 5'
CAGCTGGCACGACAGGTTT 3') TaqMan real time PCR
assays. Each reaction contained 1.5 μL cDNA, 1 × TaqMan
Universal PCR Master Mix (Applied Biosystems), 0.9 μM
of each primer and 0.25 μM of probe in a total volume of
20 μL and was run on an Applied Biosystems 7300 Real
Time PCR machine under the following conditions: 50°C
for 2 minutes, 95°C for 10 minutes followed by 40 cycles
of 95°C for 15 seconds and 60°C for 3 minutes. Tran-
script copy number was determined using the ΔΔct
method. The readthrough efficiency was calculated as the
number of transcripts detected by the eyfp to pBCKS PCR
normalised to the number of transcripts detected by the
eyfp PCR.
Statistical Analysis
All results are given as mean ± standard deviation. Chi
squared was performed using the calculator available at
http://www.physics.csbsju.edu/state/contingency.html.
All other statistical analyses, where appropriate, were per-
formed using SigmaStat for Windows version 3.0.0. Anal-
ysis was performed using Analysis of Variance (ANOVA)
coupled with a multiple comparison as specified in the
text, t-test or Chi squared.
Abbreviations
att: HIV-1 attachment sequence; bGH: bovine growth hor-
mone (gene); CRS: cis-repressive sequence; eyfp: enhanced
yellow fluorescent protein; gRNA: genomic RNA; LTR:
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